Current Report Filing (8-k)
February 24 2020 - 2:25PM
Edgar (US Regulatory)
0001320414
false
0001320414
2020-02-23
2020-02-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
current
report
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of Report
(Date of earliest event reported): February 24, 2020
SELECT MEDICAL HOLDINGS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-34465
|
|
20-1764048
|
(State or other jurisdiction of
Incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
4714 Gettysburg Road, P.O. Box 2034
Mechanicsburg, PA 17055
(Address of principal executive offices) (Zip Code)
(717) 972-1100
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
SEM
|
New York Stock Exchange (NYSE)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether either registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if either
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure.
|
Attached as Exhibit
99.1 and furnished for purposes of Regulation FD is a presentation to be given by Select Medical Holdings Corporation on Monday,
February 24, 2020 the J.P. Morgan Global High Yield & Leveraged Finance Conference.
The information in
this Current Report on Form 8-K (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation
FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned,
thereunto duly authorized.
|
SELECT MEDICAL HOLDINGS CORPORATION
|
|
|
|
Date: February 24, 2020
|
By:
|
/s/ Michael E. Tarvin
|
|
|
Michael E. Tarvin
|
|
|
Executive Vice President, General Counsel and Secretary
|
Select Medical (NYSE:SEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Select Medical (NYSE:SEM)
Historical Stock Chart
From Apr 2023 to Apr 2024